Highlights nieuwsbrief 1

Deze nieuwsbrief presenteert u de volgende lezingen:

1. Video interview: Prof. Meletios Dimopoulos, MD, about the results of the iNNOVATE trial

2. Classic Hodgkin lymphoma (cHL) patients with high-risk features have greater benefit from
    brentuximab vedotin + AVD versus ABVD compared with the overall study population

3. Anti-tumor activity of compound CAR T cells targeting both CLL1 and CD33 in a variety of CLL1+ and
    CD33+ leukemia cells in vitro and in vivo

4. Better response rates and increased MRD negativity with KRd compared to KCd in newly diagnosed
    multiple myeloma patients, including high-risk patients

5. The combination of ruxolitinib and azacitidine is well tolerated with good responses in patients
    with myelofibrosis